U.K. committee releases Orkambi documents; pricing details lacking
As NICE, NHS England and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) remain at an impasse over the pricing of cystic fibrosis drug Orkambi ivacaftor/lumacaftor, a U.K. parliamentary committee made good on its promise on Dec. 20, releasing a slew of documents from the three parties.
After the three parties failed to reach a reimbursement deal by Nov. 30, the House of Commons Health and Social Care Committee released the documents as promised in a Nov. 7 ultimatum. Vertex spokesperson Rob Clark confirmed with BioCentury Dec. 20 that there is still no deal (see "Vertex, NICE, NHS Miss Orkambi Deadline").
The batch of published documents do not